Silexion Therapeutics shares surge 52.39% intraday after announcing new preclinical data showing 97% inhibition in pancreatic cancer cells and 90% in colorectal cancer cells with its RNA interference therapy SIL204.
ByAinvest
Thursday, Jul 31, 2025 10:17 am ET1min read
SLXN--
Silexion Therapeutics Corp. surged 52.39% intraday after announcing new preclinical data showing its RNA interference therapy SIL204 achieved a 97% inhibition rate in pancreatic cancer cells and a 90% inhibition rate in colorectal cancer cells, and demonstrated efficacy against KRAS Q61H mutation for the first time. The company is a clinical-stage biotechnology firm focused on developing RNA interference therapies targeting KRAS-driven cancers, with SIL204 as its lead candidate for pancreatic cancer treatment.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet